CA2240402A1 - Anion exchange resin-containing tablets - Google Patents
Anion exchange resin-containing tablets Download PDFInfo
- Publication number
- CA2240402A1 CA2240402A1 CA002240402A CA2240402A CA2240402A1 CA 2240402 A1 CA2240402 A1 CA 2240402A1 CA 002240402 A CA002240402 A CA 002240402A CA 2240402 A CA2240402 A CA 2240402A CA 2240402 A1 CA2240402 A1 CA 2240402A1
- Authority
- CA
- Canada
- Prior art keywords
- tablets
- coated
- mixture
- anion exchange
- exchange resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
Disclosed are cholesterol-depressant, coated or non-coated tablets for oral administration, which comprise an anion exchange resin of formula (I), wherein X represents a physiologically-acceptable counter ion; and p represents an average degree of polymerization, and is larger than 10,000, silicon dioxide and crystalline cellulose, but not containing water. The non-coated tablets are preferably coated with cellulosic substances. The tablets are easy to take, as being not bitter. The dose of the tablets can be decreased, since the tablets can contain a large amount of the active ingredient. The mixture comprising the constituent components can be directly tabletted in the absence of water.
Description
WO98/16237 PCT1~7/03~0 ANION EXCHANGE RESIN-CONTAINING TABLETS
TECHNICAL FIEL~
The present invention relates to tablets and coated tablets which contain an anion exchange resin, especially a non-crosslinked anion exchange resin of a general formula (I) mentioned below, and which are useful as a cholesterol depressant. More precisely, it relates to those coated tablets with high stability, in which the content of the active ingredient i6 increafied in order that they can be administered with ea~e and that the number of the tablet6 to be administered can be decreased.
In addition, the invention also relates to a method for producing the tablets and coated tablets.
BAC~GROUND ART
Colestyramine of a crosslinked type, which is a conventional cholesterol depressant, is problematic in that its amount to be administered is large (8 to 16 g/day) and that it mu6t be administered in the form of its suspension.
Therefore, many studies have heretofore been made to produce tablets and coated tablets of anion exchange resins For example, a method has been reported of coating tablets of a solid colestyramine resin having a water content of W 098/16237 PCT/Jr97/03720 from B to 14 % with a melt of polyethylene glycol and stearic acid in the presence of no solvent to give coated tablets, which do not swell in the mouth (see Japanese Patent Application Laid-Open No. 3-236326).
Regarding tablets of an imidazole-type anion exchange resin (see Japanese Patent Application Laid-Open No. 60-209523), known are a method of producing those tablets in the presence of a predetermined amount of water (see Japanese Patent Application Laid-Open No. 2-286621); a method of producing coated tablets by coating those tablets as prepared in the presence of a predetermined amount of water, with hydroxypropyl cellulose or the like (see Japane~e Patent Application No. 4-320155 (published before examination as Laid-Open No. 6-157325)); and a method of producing tho~e tablets in the presence of a predetermined amount of water and silicon dioxide (see Japanese Patent Application Laid-Open No. 7-97330).
In addition, also known are methods of producing coated, anion exchange resin tablets with good moisture-resistant stability, which comprise tabletting an anion exchange resin in the presence of water to give non-coated tablets followed by coating them with a cellulosic substance or the like, and in which the hygroscopicity of the anion exchange resin in the non-coated tablets is lowered to thereby reduce the variation in the diameter of WO98116237 PCTJ~7/03720 each non-coated tablet relative to the ambient humidity (see Japane6e Patent Application Laid-Open Nos. 7-97330 and 6-157325). Those known methods are to coat the cores of non-coated tablets which contain a predetermined amount of water to thereby reduce the variation in the diameter in each non-coated tablet relative to the ambient humidity.
However, the conventional methods require the addition of a predetermined amount of water to the hygroscopic anion exchange resins being tabletted.
On the other hand, we, the present inventors have already reported that a non-crosslinked anion exchange resin of the formula (II):
Rl \
I
C H ~
C O R2 X - ~ ( II) 2)~ R l 1~
wherein Rl represents an aralkyl group having from 7 to l0 carbon atoms, or an alkyl group having from l to 20 carbon atoms; R2 and R3 are the 6 ame or different and each independently represents a lower alkyl group having from l to 4 carbon atoms; R4 represents a hydrogen atom or a lower WO98116237 pcTtn~7lo372 alkyl group having from l to 4 carbon atoms; X represents a physiologically-acceptable counter ion; n represents an integer of from l to 3; and p represents an average degree of polymerization of from lO to lO,000, is extremely useful as a cholesterol depressant (see W0~3/13781). As being a non-crosslinked linear polymer, this anion exchange resin doe~ not swell to increase its volume, unlike crosslinked polymers such as colestyramine, and therefore has no unfavorable side effects such as abdominal distention and constipation. In addition, the effective absorption of bile acid by the anion exchange resin per its unit weight is large. Accordingly, the anion exchange resin is very useful.
However, this resin is soluble in water and is highly bitter, and in addition, it is highly hygroscopic and deliquescent. Therefore, the novel, non-crosslinked cholesterol depressant comprising the compound of formula (II) is problematic in that, if tabletted in any of the conventional methods that require water in the mixing step, it is formed into tablets with poor strength and stability since it~ flowability and tablettability is very poor.
Even if the chole6terol depressant comprising the compound of formula (II) i6 tabletted in the absence of water, the resulting tablets are still problematic in that they are very bitter because of the strong bitterness intrinsic to the compound of formula (II) itself. The dose of the compound of formula (II), though varying depending on the case to which it is administered, is relatively large or is generally from 0.1 to 9 g/day, preferably from 0.1 to 5 g~day. Tablets comprising the compound of formula (II) and containing a large amount of vehicles in order to reduce the bitterness of the compound are problematic in that the number of the tablets to be administered at a time shall be large.
In order to produce practical medicine products comprising the compound of formula (II) with such extremely high usefulness, it is desired to formulate the compound into highly-stable preparatione without strong bitterness while adding thereto the smallest possible amount of vehicles as possible.
Having regard to the above problems, the present inventors already found that a mixture comprising the cholesterol depressant, non-crosslinked cation exchange resin of formula (II), along with at least silicon dioxide and crystalline cellulose could be formed into tablets in the absence of water on an industrial scale, that the cores of the thus-formed, non-coated tablets could be coated with a coating material comprising a cellulosic substance to give coated tablets, and that those coated tablets could WO98/16237 PCT/~97/03720 overcome the problems in the art (see Japanese Patent Application No. 8-235718).
The non-crosslinked anion exchange resins of formula (II) have an average degree of polymerization of not larger than 10,000. As a result of additional studies, the inventors further found that non-crosslinked anion exchange resins of a general formula (I) mentioned below, having an average degree of polymerization of larger than 10,000, take excellent pharmaceutical effects as a cholesterol depressant.
The inventors 6till further found that the formulation of those resins of formula (I) involves the same problems as those in the formulation of the resins of formula (II) having an average degree of polymerization of from 10 to 10,000. In particular, the non-cros61inked anion exchange re~ins of formula (I) having an average degree of polymerization of larger than 10,000 are highly hygroscopic, therefore, the known tabletting methods requiring a predetermined amount of water were not directly applicable.
DISCLOSURE OF THE INVENTION
Having regard to the above-mentioned problems, the inventors have assiduously studied and, as a result, have found that a mixture comprising a non-crosslinked anion exchange resin of the following formula (I):
PCT1~97/03720 wn ~16~37 C1~
CO 1H3X~
\ o - (C~2)2 - N~ - CH2 ~ ~ /~ /
wherein X represents a physiologically-acceptable counter ion; and p represents an average degree of polymerization and i6 larger than lO,000, and at least silicon dioxide and crystalline cellulose can be formed into tablets on an industrial scale, without adding water thereto, and that the cores of the non-coated tablets as obtained above can be coated with a coating agent comprising cellulose in order to coat the tablets, and also that those non-coated and coated tablets are free from the above-mentioned problems. In addition, the inventors have further found that, by that the non-coated tablets which are highly hygroscopic are coated with such a coating agent comprising cellulose, the coated tablets do not only control the bitter of the compound of formula (I) but also prevent hygroscopic of the non-coated tablets without adding water content. Therefore these tablets are stable in long-term 6torage.
The present invention provides anion exchange resin-containing tablets as formed by tabletting a mixture comprising the non-crosslinked anion exchange resin of formula (I) ~nd at least silicon dioxide and crystalline cellulose but not containing water. The invention also provides a method for producing anion exchange resin-containing tablets, which comprises adding at least silicon dioxide and crystalline cellulose to the non-crosslinked anion exchange resin of formula (I) but not adding water thereto to give a mixture, followed by tabletting the mixture.
The invention further provides coated and non-crosslinked anion exchange resin containing tablets as produced by tabletting a mixture comprising the non-crosslinked anion exchanqe resin of formula (I) and at least silicon dioxide and cry~talline cellulose but not containing water followed by coating the resulting non-coated tablets with a coating material comprising a cellulosic substance, and provides a method for producing such coated tablets.
The preparations of the invention are characterized in that they contain a minimized amount of vehicles, or that is, they contain a highest possible amount of the active ingredient. The preparations of the invention can be WOg8/16237 PCT/~7/03720 produced in any continuous production lines on an industrial scale.
If the mixture to be tabletted into tablets according to the invention does not contain either one of silicon dioxide and crystalline cellulose, not only its ta~lettability is poor but also the fluctuation in the weight of the tablets formed ifi great, and in addition, the surfaces of the tablets formed are cracked and the edges thereof are chipped, resulting in that the yield of tablets with acceptable quality is greatly lowered (see Examples 4 and 5 in the present application).
BEST MODES OF CARRYING OUT THE INVENTION
The non-crosslinked anion exchange resin of formula (I)-for use in the present invention is described in detail hereinunder.
The counter ion X in the non-crosslinked anion exchange resin of formula (I) for use in the invention is not specifically defined if it is a physiologically-acceptable counter ion. For this, however, preferred are halides, sulfates and phosphates; more preferred are halide ions such as chloride, bromide, fluoride and iodide ions.
The average degree of polymerization p of the non-crosslinked anion exchange resin of formula (I) for use in the invention i~ larger than l0,000, preferably from larger than 10,000 to 50,000, more preferably from larger than 10,000 to 30,000, even more preferably from larger than 10,000 to 15,000. More concretely, the average degree of polymerization p is preferably from 10,001 to 50,000, more preferably from 10,001 to 30,000, even more preferably from 10,001 to 15,000.
One preferred example of the non-cros~linked anion exchange resin of formula (I) for use in the invention is poly(acryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride) having an average degree of polymerization, p, of from 10,001 to 30,000, more preferably from 10,001 to 15,000.
In order to obtain an average degree of polimerization p, the ordinary ways may be performed, preferably the following way may be performed;
Firstly, a molecular weight was measured with GPC
system aparatus (SHIMAZU SEISAKUSHO K.K. ), RI (differential refractive index detection) as a detector and TOSOH
G600OPWXL-G300OPWXL as a column, Column Temperatures 40 C
Mobile Phase: 50 mM-NaCl solution Flow Rate: 1 mL/min.
and then the measured molecular weight was divided by a basic structure unit (a molecular weight of monomer).
WO98116237 PCT/~7/03720 The non-crosslinked anion exchange resin of formula (I) for use in the invention can be produced in any ordinary method in which the corresponding monomers are prepared and then polymerized in an ordinary manner. More concretely, quaternary ammonium salts of the corresponding monomers are prepared and are polymerized to a sufficient degree in the presence of a polymerization initiator such as a radical polymerization initiator. If the polymerization is effected under a mild condition, the resulting polymer may have a small average degree of polymerization, p. Therefore, it iB desired to effect the polymerization to a sufficient degree.
Now, the preparations of the invention are described hereinunder.
The amount of the compound of formula ~I) to be in the non-coated tablets of the invention may be from 50 to 95 %
by weight, preferably from 70 to gO % by weight, more preferably from 75 to 90 % by weight, relative to the total weight of each non-coated tablet.
Silicon dioxide and crystalline cellulose to be used in the invention are not specifically defined, provided that their oral administration is admitted. From the commercial viewpoint, however, preferred are those which have heretofore been used in conventional oral medicines.
PCT/~7/03720 Wo ~/16237 Silicon dioxide is to well fluidize the mixture to be tabletted. For example, employable is colloidal silicon dioxide hydrate (e.g., white carbon), silicon dioxide (e.g.
silica gel, 6ilicic anhydride) and so on. Preferred is anhydrous, fine particulate silicon dioxide or light ~ilicic anhydride. Silicon dioxide for use in the invention has an apparent specific gravity of from 20 g/liter to 70 g/liter, preferably from 20 g/liter to 50 g/liter. Preferred is light silicic anhydride having a ~mall apparent specific gravity. The amount of silicon dioxide to be added may be from O.Ol to 5 % by weight, preferably from O.l to 3 % by weight, more preferably from O.l to l % by weight, relative to the total weight of each no~-coated tablet.
- Crystalline cellulose is preferably microcrystalline cellulose, and may have a mean grain size of from 5 to 50 microns, preferably from lO to 50 microns, more preferably from l~ to 30 microns. Its amount to be added may be from O.l to 30 % by weight, preferably from l to 30 % by weight, more preferably from lO to 30 ~ by weight, relative to the total weight of each non-coated tablet.
Regarding silicon dioxide, especially light ~ilicic anhydride added to the mixture to be tabletted in the invention, the increase in its amount and the decrease in it~ apparent specific gravity (bulk density) results in the W 098/16237 PCT/Jr97/03720 increase in the fluidity of the powdery mixture, while often worsening the tablettability (into compact tablets) of the mixture. Therefore, i~ silicon dioxide is added to the mixture in an amount of 5 parts or more, relative to the compound of formula (I), the tablettability of the mixture is poor thereby resulting in that the tablets formed are much cracked.
On the other hand, regarding crystalline cellulose added to the mixture to be tabletted in the invention, the increase in its amount and the decrease in its mean grain size results in the increase in the tablettability (into compact tablets) of the powdery mixture, while often lowering the fluidity of the mixture. In particular, if crystalline cellulose is added to the mixture in an amount of larger than 30 parts relative to the compound of formula (I), the weight of the tablets formed greatly fluctuates.
Since there is no significant reason for adding crystalline cellulose to the mixture in such an amount of larger than 30 parts, it ie desirable to add any inexpensive vehicle such as lactose to the mixture if the addition of a large amount of vehicles is needed.
Discussing it in more detail, the invention provides anion exchange resin-containing tablets as formed by tabletting a mixture comprising the non-crosslinked anion exchange resin of formula (I), and containing at least WO98/16237 PCTm~7103720 light silicic anhydride having a 6mall apparent specific gravity of from 20 gtliter to 70 g/liter, preferably from 20 g/liter to 50 g/liter, and crystalline cellulose having a mean grain size of from 10 microns to 50 microns, preferably from 10 microns to 30 micron~, but not containing water, and provide~ a method for producing the tablets.
Also in more detail, the invention provides anion exchange resin-containing tablets as formed by tabletting a mixture comprising the non-crosslinked anion exchange resin of formula tI), and containing at least silicon dioxide having a small apparent specific gravity of from 20 g~liter to 50 gtliter, preferably from 20 g/liter to 40 g/liter, and crystalline cellulose having a mean grain size of from 10 microns to 50 microns, preferably from 10 microns to 30 microns, but not containing water, in which the anion exchange resin i~ from 50 to 95 ~ by weight, preferably from 70 to 90 ~ by weight, more preferably from 75 to 90 ~
by weight, relative to the total weight of each tablet, and provides a method for producing the tablets.
The invention further provides coated, non-crosslinked anion exchange resin-containing tablets as produced by coating the non-coated tablets with a coating material comprising a cellulosic substance, and provide6 a method for producing the coated tablets.
Wo98116237 The non-coated tablets of the invention, which may be the cores of the coated tablets, may contain, in addition to the above-mentioned silicon dioxide and crystalline cellulose, any other conventional additives that are generally employable in forming tablets, within the range not interfering with the object of the invention. For example, the tablets of the invention may optionally contain any of vehicles, for example, bioses and monoses such as lactose, sucrose, glucose, mannitol and sorbitol, and starches such as potato starch, wheat starch, corn starch and rice starch; lubricants, for example, inorganic substances such as calcium phosphate and calcium sulfate, higher fatty acids and their metal salts (e.g., stearic acid, magnesium stearate), higher alcohols, talc, and synthetic aluminium silicate; disintegrators such as starches, sodium or potassium salt of carboxymethyl cellulose, methyl cellulose, carboxymethyl starch and sodium alginate; and binders such as starches, sucrose, gelatin, arabic gum, methyl cellulose, sodium carboxymethyl cellulose, polyvinyl pyrrolidone and polymethyl pyrrolidone The non-coated tablets of the invention, which may be the cores of the coated tablets, can be produced by mixing the constituent components and tabletting the resulting mixture. The order of adding the components to give the mixture is not specifically defined. Preferably, however, crystalline cellulose and silicon dioxide are first mixed, and then the compound of formula (I) is added thereto preferably gradually, and mixed togethe~. Then, the optional components may be added to and mixed with the resulting mixture.
The tabletting pressure is not specifically defined, but is preferably not larger than 2 tons.
The cellulosic substance to be in the coating material which is used in coating the non-coated tablets in the invention is not specifically defined, provided that it is a pH-independent and water-soluble one. Concretely, for example, employable are hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and methyl cellulose.
Preferred i8 hydroxypropylmethyl cellulose.
Those cellulosic substances may be used singly, but if desired, may be used along with a small amount of wax, titanium oxide, talc, hydroxypropyl cellulose with a low degree of substitution, polyethylene glycol, triethyl citrate or the like. In view of the strength of the coated film and of the economical aspect, polyethylene glycol (Macrogol) is preferably added to the coating material.
Regarding the concentration of the cellulosic substance in the coating liquid, if it iB too high, the amount of the cellulosic substance to be in the coated film is too much. Therefore, too high concentration of the cellulosic substance in the coating liquid is unfavorable.
Preferably, the concentration of the cellulosic substance is smaller than 20 % by weight, more preferably from 6 to 15 % by weight or so. Where polyethylene glycol (Macrogol) is added to the coating liquid, it~ concentration is preferably from 1 to 50 % by weight or so, more preferably from 5 to 40 % by weight or 60, relative to the cellulosic substance.
Acid-soluble, film-forming substances are also employable for coating the non-coated tablets. For example, employable are coating materials capable of dissolving in gastric acids, such as diethylamino methacrylate, polyvinyl acetal diethylaminoacetate (AEA), dimethylaminoethyl methacrylate-methyl methacrylate copolymer (be on the market as EUDRAGIT (methyl methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate copolymer))~ cellulose acetate N,N-di-n-butylhydroxypropyl ether (CABP), etc.
The coating method is not specifically defined, but preferred is spray-coating.
The amount of the coating material to be applied to the non-coated tablets is preferably such that the coated film may be from 1 to 10 % by weight relative to each non-coated tablet (core). To mask the bitterness of the non-coated tablets, the tablets may be coated with the coated film of 1 % by weight or more. However, even if the WO98116237 PCT1~97103720 tablets are coated with the film of larger than 10 % by weight, such produces no more advantage~. Most preferably, the coated film is about 3 % by weight. Prior to coating them, it is preferable to measure the water content of the non-coated tablets (cores), and the coating is continued until the increa~e in the water content of the coated tablets is no more recognized.
EXAMPLES
Now, the invention i6 described in more detail hereinunder with reference to the following Examples.
However, it is obvious that the invention is not restricted ~y those Examples but may encompass any other changes and modifications without overstepping its scope and spirit.
Example 1:
(1) Mixing Step:
To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Method:
As in the mixture formulation mentioned below, 1000 g of crystalline cellulose and 50 g of light silicic anhydride were weighed, put into the mixer, and mixed therein for 5 minutes.
The total amount of poly(acryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride) (of formula (I) where X
is chloride ion - hereinafter referred to as "compound 1") having an average degree of polymerization of 12,000 was divided into four portions, which were separately added to the mixture one after another at intervals of 5 minutes, with still mixing it.
Next, 50 g of magnesium stearate was weighed, added to the mixture and further mixed for 1 minute.
(1-2) Mixture Formulation (10 kg):
Compound 1 8900 g Crystalline Cellulose 1000 g (be on the market as Avicel PH-F20 (average grain 6ize: 17 microns)) Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent specific gravity (bulk density):
30 g/liter) (2) Tabletting Step:
To form the mixture into tablets, used was the following tabletting device:
Tabletting Device: Rotary tabletting machine, HT-AP15SS
(Hata Ironworks Co.) WO98/16237 PCT/~7/03720 (2-l~ Tabletting Condition Number of revolution: 35 rpm Thickness of tablet: ~ mm Hardness of tablet: 7 or more Vertical pres6ure for tabletting: 2 tons or less Feeding system: forced feeder used (3) Coating Step:
To coat the non-coated tablets, used was the followLng coating devices Coating Device: Dria Coater 650 (POWREX) (3-1) Coating Method:
7 kg of the non-coated tablets produced in the previous step (2) were put into a coating pan, in which the temperature of the vapor to be absorbed by the tablets was kept at 80~C without revolving the pan (number of revol~tion: 0 rpm) until the temperature of the vapor as discharged from the pan became constant. In this stage, the temperature of the discharged vapor was confirmed to be 50~C or higher. 20 tablets were sampled out of the pan and weighed. Then, they were ground, and their water content was measured. After this, a coating liquid having the composition mentioned below was sprayed over the tablets in the pan at a spraying rate of 12 g/min, while the pan was revolved at 7 rpm. After 30 minutes, the number of revolution of the pan was changed to 15 rpm, and the spraying was further continued at a spraying rate of about 18 g/min. At regular intervals during the spraying, 20 tablets were sampled out, and their weight and water content were measured. When no increa6e in the water content of the sampled, coated tablets was recognized and when the weight of the coated tablets became 103 % of the non-coated tablets, the spraying was stopped. Then, the pan was still revolved at 5 rpm for about 60 minutes to dry the coated tablets.
(3-2) Coating Liquid Formulations Hydroxypropylmethyl Cellulose 2910400 g Macrogol 6000 120 g Ion-exchanged Water 4600 g Example 2 (1) Mixing Steps To mix the constituent components, used was the following mixing device.
Mixing Devices V-type mixer, FMV100 (~OWREX) (1-1) Mixing Method:
AB in the mixture formulation mentioned below, 2000 g of cry6talline cellulose and 50 g of light silicic WO98/16237 pcTl~s7lo372o anhydride were weighed, put into the mixer, and mixed therein for 5 minutes.
The total amount of compound l wa~ divided into four portions, which were separately added to the mixture one after another at intervals of 5 minutes, with 6till mixing it.
Next, 50 g of magnesium stearate was weighed, added to the mixture and further mixed for l minute.
(l-2) Mixture Formulation (lO kg) Compound l 7900 g Crystalline Cellulose lO00 g (be on the market as Avicel PH-3lO (average grain sizes 40 microns)) Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent specific gravity (bulk den~ity):
50 g/liter) (2) Tabletting Step, Coating Step:
In the same manner as in Example l, the mixture was tabletted and coated.
Example 3 (l) Mixing Steps To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Method:
As in the mixture formulation mentioned below, 1000 g of crystalline cellulose, 550 g of lactose and 50 g of light silicic anhydride were weighed, put into the mixer, and mixed therein for 5 minutes.
The total amount of compound 1 was divided into four portions, which were separately added to the mixture one after another at intervals of 5 minutes, with still mixing it.
Next, 50 g of magne~ium stearate wa6 weighed, added to the mixture and further mixed for 1 minute.
(1-2) Mixture Formulation (10 kg):
Compound 1 8350 g Crystalline Cellulose 1000 g (be on the market as Avicel PH-F20 (average grain size: 17 microns)) Lactose 550 g Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent 6pecific gravity (bulk density):
W O98/16237 PCT/JPg7/~3720 50 g~liter) (2) Tabletting Step, Coating Step:
In the same manner as in Example 1, the mixture wa~
tabletted and coated.
Example 4 (1) Mixing Step, Tabletting Step:
In the same manner as in Example 1, the constituent components were mixed and tabletted.
(2) Coating Step:
(2-1) Coating Method~
~ n the same manner as in Example 1, the non-coated tablets were coated with the coating liquid mentioned below, and then dried. Next, 5 g of carnauba wax was added to the coating pan still containing the dried, coated tablets therein, and the pan was further revolved at 5 rpm for 5 minutes.
(2-2) Coating Li~uid Formulation:
Hydroxypropylmethyl Cellulose 2910400 g Macrogol 6000 120 g Titanium oxide 28 g Ion-exchanged Water 4000 g PCT/~7/03720 Wo ~116~7 ~2-3) Lubricant:
Powdery Carnauba Wax 5 g Example 5 Non-coated tablets were produced in the same manner as in Example l-(l) and (2), except that poly(acryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride (of formula (I) where X is chloride ion)) having an average degree of polymerization of 13,000 was used.
Next, these were coated in the same manner as in Example l-(3) to obtain coated tablets.
Example 6 Non-coated tablets were produced in the same manner as in Example l-(l) and (2), except that poly(acryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride (of formula (I) where X is chloride ion)) having an average degree of polymerization of l~,000 was used.
Next, these were coated in the same manner as in Example l-(3) to obtain coated tablets.
Comparative Example l (l) Mixing Step:
To mix the con6tituent components, used was the following mixing device.
pcTl~s7l~372o WO g8/16237 Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Method:
As in the mixture formulation mentioned below, 1000 g of crystalline cellulose and 50 g of light ~ilicic anhydride were weighed, put into the mixer, and mixed therein for 5 minutes.
The total amount of compound 1 was divided into four portions, which were separately added to the mixture one after another at intervals of 5 minute~, with still mixing it.
Next, 50 g of magnesium stearate was weiqhed, added to the mixture and further mixed for 1 minute.
Since it was difficult to mix compound 1 and water, ~90 g of water sprayed over the sy~tem being mixed.
(1-2) Mixture Formulation (10 kg):
Compound 1 8010 g Water 890 g Crystalline Cellulose 1000 g (be on the market as Avicel PH-F20 (average grain size: 17 microns)) Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent specific gravity (bulk density) t 30 g/liter) Comparative Example 2:
(1) Mixing Step:
To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Method:
As in the mixture formulation mentioned below, 1000 g of crystalline cellulose and 50 g of light silicic anhydride were weighed, put into the mixer, and mixed therein for ~ minutes.
The total amount of compound 1 was divided into four portions, which were separately added to the mixture one after another at intervals of S minutes, with still mixing it.
Next, 50 g of magnesium stearate was weighed, added to the mixture and further mixed for 1 minute.
(1-2) Mixture Formulation (10 kg):
Compound 1 ~900 g Crystalline Cellulose 1000 g (be on the market as Avicel PH-301 (average grain size: 40 microns)) Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent specific gravity (bulk density):
30 g/liter) WO98/16237 PCT/~97/03720 (2) Tabletting Step, Coating Step:
In the same manner as in Example l, the mixture was tabletted and coated.
Comparative Example 3:
(l) Mixing Steps To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMVl00 (POWREX) (l-l) Mixing Method:
As in the mixture formulation mentioned below, l000 g of crystalline cellulose and 50 g of light silicic anhydride were weighed, put into the mixer, and mixed therein for S minutes.
The total amount of compound l was divided into four portions, which were separately added to the mixture one after another at intervals of 5 minutes, with still mixing it.
Next, 50 g of magnesium stearate wa~ weighed, added to the mixture and further mixed for l minute.
(1-2) Mixture Formulation (l0 kg):
Compound l 8900 g Cry6talline Cellulose l000 g (be on the market as Avicel P~-302 (average grain sizes l20 microns)) Magneslum Stearate 50 q Light Silicic Acid 50 g (apparent specific gravity (bulk densi~y):
30 g/liter) (2) Tabletting Step, Coating Step:
In the same manner as in Example 1, the mixture was tabletted and coated.
Comparative Example 4:
(1) Mixing Step:
To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Methods A~ in the mixture formulation mentioned below, 50 g of light silicic anhydride was weighed and put into the mixer.
The total amount of compound 1 was divided into four portions, which were ~eparately added to the anhydride one after another at intervals of 5 minutes, with mixing it.
Next, 50 g of magneEium stearate wa~ weighed, added to the mixture and further mixed for 1 minute.
(1-2) Mixture Formulation (10 kg):
Compound 1 9900 g Magnesium Stearate 50 g PC~1~97103720 Light Silicic Acid 50 g ~apparent specific gravity (bulk density):
30 g/liter) (2) Tabletting Step, Coating Step:
In the same manner as in Example l, the mixture wa~
tabletted and coated.
Comparative Example 5:
(l) Mixing Step:
To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMVl00 (POWREX~
(l-l) Mixing Method:
As in the mixture formulation mentioned below, l000 g of crystalline cellulose was weighed and put into the mixer.
The total amount of compound l was divided into four portions, which were separately added to the crystalline cellulose one after another at intervals of 5 minutes, with mixing it.
Next, 50 g of magnesium stearate was weighed, added to the mixture and further mixed for l minute.
(1-2) Mixture Formulation (l0 kg):
Compound l 8950 g Crystalline Cellulose l000 g PCT/~7/03720 (trade name: Avicel PH-F20 (average grain size:
l7 micron6)) Magne~ium Stearate 50 g (2) Tabletting Step, Coating Step:
In the same manner as in Example l, the mixture was ta~letted and coated.
Comparative Example 6:
(l) Mixing Step:
To mix the constituent components, used wa6 the following mixing device.
Mixing Device: V-type mixer, FMVl00 (POWREX) (l-l) Mixing Method:
A6 in the mixture formulation mentioned below, 9950 g of compound l and 50 g of magnesium stearate were weighed, put into the mixer, and mixed therein for l minute.
(1-2) Mixture Formulation (l0 kg1s Compound l 9950 g Magnesium Stearate 50 g (2) Tabletting Step, Coating Step:
In the 6ame manner a6 in Example l, the mixture was tabletted and coated.
Comparative Example 7:
rCTlJP97103720 Wo98116237 Non-coated tablets were produced in the same manner as in Example 1, but these were not coated herein.
Te~t Example 1:
The samples prepared above were tested for their powder flowability and compres~ibility (tablettability).
A~ in Table 1, the fluctuation in the weight of non-coated tablets indicate~ the powder ~lowa~ility, and the frequency of chipping and crackin~ of coated tablet6, for which the non-coated tablets were produced by compres 6 ing the powdery mixture at a pressure of 2 t~ns or lower, indicates the compressibility. Since the non-coated tablets were highly hygroscopic, their weight increased in the abrasion ~est.
The outward appearance of the tested tablet~ indicates their compressibility.
The test data are shown in Table 1.
Table 1 Fluctuation in Weight of Non-coated Chipplng, Cracking Tablettability TablP-s CXAIIIP e sma no A
Examp e _ sma no A
Examp e sma no A
Co~"part~ ~e Example 1u"~abletlable Comparatlve Example 2 small surface cracked C
Comparative surface cracked, Example3 small edges chipped C
Co",par~ e surface cracked, Example 4 small edges chipped C
Comparatlve Example 5 medium no B
Comparative surface cracked, Example 6 great edges chipped D
W O 9%/16237 PCT/JP97/03720 In Comparative Example 1 in which the components were mixed along with water, the components could not be well mixed because of their deliquescence and cobwebbing, and could not be tabletted.
In all Examples and Comparative Examples in which the components were mixed in the absence of water, it wa6 possible to tablet the mixtures and coat the non-coated tablets. However, only sample~ in Example 1, Example 2 and Example 3 involved no problem with respect to their powder flowability and compressibility.
In Comparative Example 4, crystalline cellulose was not used; in Comparative Example 5, light silicic anhydride was not used; and in Comparative Example 6, both the two were not used. In the absence of crystalline cellulose, the tablettability (compressibility~ of the mixture i8 extremely poor, and the surface of the coated tablets was cracked. In the absence of light silicic anhydride, the powder flowability of the mixture was poor, and the fluctuation in the wei~ht of the tablets increased. In the absence of the two, crystalline cellulose and light silicic anhydride, the fluctuation in the weight of the tablet~
greatly increased, and the tablets were cracked and chipped, or that is, the tablettability of the mixture was poor.
WO98/lQ37 PCT/~97/03720 In Comparative Example 2, crystalline cellulose having a mean grain size of 40 microns was used; and in Comparative Example 3, crystalline cellulose having a mean grain size of 120 microns was used. In those two, used was light silicic anhydride having an apparent specific gravity (bulk density) of 30 g/liter. Even though crystalline cellulose having a large mean grain size was used, the mixture could be tabletted if light silicic anhydride having a small apparent 6pecific gravity (bulk density) was added thereto (see Example 2). However, as in those Comparative Examples, if light 8i1iCiC anhydride having a large apparent specific gravity (bulk density) was added to the mixture, it is known that the tablets were cracked or chipped and the tablettability of the mixture was poor.
AB in Example l in which were used light silicic anhydride having a small apparent specific gravity (bul~
density) and crystalline cellulose having a small mean grain size, the tablets formed had a high chemical (active ingredient) content. Thus, the tablets of the invention are advantageous in that the dose of the tablets can be decreased. In addition, the mixture formulation for the tablets of the invention can be stably tabletted in continuous production plants directly after the step of mixing it, without requiring any additional step of granulating it.
PCT/~97103720 Test Example 2:
The tablets of the invention are deformed when their water content is larger than 7 %. In addition, after having absorbed more water, they become deliquescent. The stability of the tablets can be ensured by coating them.
To evaluate their stability, the tablets of Example l, Example 4 and Comparative Example 7 were kept at 60~C and 90 % RH for 20 minutes, and the presence or absence of the change in their form was checked. In addition, they were tested for their bitterness by putting them in the mouth for 30 seconds. The test data are shown in Table 2.
Table 2 Defo~ a~lon ~ittt~ ness Ex~mple no ~ o Ex~mple ~ no \ o Coi"ph~tve ExAmple 7 yes Yes The data indicate that the stability of the coated tablets is high and that the coated tablet~ are easy to take as their bitterness was masked.
The tablets obtained in Examples 5 and 6 were also subjected to the same tests in Test Examples l and 2, and produced the same good results.
The non-crosslinked anion exchange resin of formula (I) of the invention exhibits excellent pharmaceutical WO98/16237 PCT/~7/03720 effects and is useful as a cholesterol depressant for oral administration. According to the tabletting method of the invention, the peroral cholesterol depre6sant of formula (I) with good pharmaceutical effects can be formed into medicines that are easy to take.
INDUSTRIAL APPLICABILITY
The invention provides anion exchange resin-containing, cholesterol-depressant tablets for oral administration, which are superior to any other conventional ones in that their do6e may be decrea~ed and that they are ea6y to take.
In addition, the tabletting method of the invention is greatly advantageous in that it does not require any additional granulating step. The tablets of the invention may be coated with a coating material compri6ing a cellulosic material, and the resulting coated tablets are easier to take as being not bitter.
The method of the invention is advantageous as being applicable to industrial plants.
TECHNICAL FIEL~
The present invention relates to tablets and coated tablets which contain an anion exchange resin, especially a non-crosslinked anion exchange resin of a general formula (I) mentioned below, and which are useful as a cholesterol depressant. More precisely, it relates to those coated tablets with high stability, in which the content of the active ingredient i6 increafied in order that they can be administered with ea~e and that the number of the tablet6 to be administered can be decreased.
In addition, the invention also relates to a method for producing the tablets and coated tablets.
BAC~GROUND ART
Colestyramine of a crosslinked type, which is a conventional cholesterol depressant, is problematic in that its amount to be administered is large (8 to 16 g/day) and that it mu6t be administered in the form of its suspension.
Therefore, many studies have heretofore been made to produce tablets and coated tablets of anion exchange resins For example, a method has been reported of coating tablets of a solid colestyramine resin having a water content of W 098/16237 PCT/Jr97/03720 from B to 14 % with a melt of polyethylene glycol and stearic acid in the presence of no solvent to give coated tablets, which do not swell in the mouth (see Japanese Patent Application Laid-Open No. 3-236326).
Regarding tablets of an imidazole-type anion exchange resin (see Japanese Patent Application Laid-Open No. 60-209523), known are a method of producing those tablets in the presence of a predetermined amount of water (see Japanese Patent Application Laid-Open No. 2-286621); a method of producing coated tablets by coating those tablets as prepared in the presence of a predetermined amount of water, with hydroxypropyl cellulose or the like (see Japane~e Patent Application No. 4-320155 (published before examination as Laid-Open No. 6-157325)); and a method of producing tho~e tablets in the presence of a predetermined amount of water and silicon dioxide (see Japanese Patent Application Laid-Open No. 7-97330).
In addition, also known are methods of producing coated, anion exchange resin tablets with good moisture-resistant stability, which comprise tabletting an anion exchange resin in the presence of water to give non-coated tablets followed by coating them with a cellulosic substance or the like, and in which the hygroscopicity of the anion exchange resin in the non-coated tablets is lowered to thereby reduce the variation in the diameter of WO98116237 PCTJ~7/03720 each non-coated tablet relative to the ambient humidity (see Japane6e Patent Application Laid-Open Nos. 7-97330 and 6-157325). Those known methods are to coat the cores of non-coated tablets which contain a predetermined amount of water to thereby reduce the variation in the diameter in each non-coated tablet relative to the ambient humidity.
However, the conventional methods require the addition of a predetermined amount of water to the hygroscopic anion exchange resins being tabletted.
On the other hand, we, the present inventors have already reported that a non-crosslinked anion exchange resin of the formula (II):
Rl \
I
C H ~
C O R2 X - ~ ( II) 2)~ R l 1~
wherein Rl represents an aralkyl group having from 7 to l0 carbon atoms, or an alkyl group having from l to 20 carbon atoms; R2 and R3 are the 6 ame or different and each independently represents a lower alkyl group having from l to 4 carbon atoms; R4 represents a hydrogen atom or a lower WO98116237 pcTtn~7lo372 alkyl group having from l to 4 carbon atoms; X represents a physiologically-acceptable counter ion; n represents an integer of from l to 3; and p represents an average degree of polymerization of from lO to lO,000, is extremely useful as a cholesterol depressant (see W0~3/13781). As being a non-crosslinked linear polymer, this anion exchange resin doe~ not swell to increase its volume, unlike crosslinked polymers such as colestyramine, and therefore has no unfavorable side effects such as abdominal distention and constipation. In addition, the effective absorption of bile acid by the anion exchange resin per its unit weight is large. Accordingly, the anion exchange resin is very useful.
However, this resin is soluble in water and is highly bitter, and in addition, it is highly hygroscopic and deliquescent. Therefore, the novel, non-crosslinked cholesterol depressant comprising the compound of formula (II) is problematic in that, if tabletted in any of the conventional methods that require water in the mixing step, it is formed into tablets with poor strength and stability since it~ flowability and tablettability is very poor.
Even if the chole6terol depressant comprising the compound of formula (II) i6 tabletted in the absence of water, the resulting tablets are still problematic in that they are very bitter because of the strong bitterness intrinsic to the compound of formula (II) itself. The dose of the compound of formula (II), though varying depending on the case to which it is administered, is relatively large or is generally from 0.1 to 9 g/day, preferably from 0.1 to 5 g~day. Tablets comprising the compound of formula (II) and containing a large amount of vehicles in order to reduce the bitterness of the compound are problematic in that the number of the tablets to be administered at a time shall be large.
In order to produce practical medicine products comprising the compound of formula (II) with such extremely high usefulness, it is desired to formulate the compound into highly-stable preparatione without strong bitterness while adding thereto the smallest possible amount of vehicles as possible.
Having regard to the above problems, the present inventors already found that a mixture comprising the cholesterol depressant, non-crosslinked cation exchange resin of formula (II), along with at least silicon dioxide and crystalline cellulose could be formed into tablets in the absence of water on an industrial scale, that the cores of the thus-formed, non-coated tablets could be coated with a coating material comprising a cellulosic substance to give coated tablets, and that those coated tablets could WO98/16237 PCT/~97/03720 overcome the problems in the art (see Japanese Patent Application No. 8-235718).
The non-crosslinked anion exchange resins of formula (II) have an average degree of polymerization of not larger than 10,000. As a result of additional studies, the inventors further found that non-crosslinked anion exchange resins of a general formula (I) mentioned below, having an average degree of polymerization of larger than 10,000, take excellent pharmaceutical effects as a cholesterol depressant.
The inventors 6till further found that the formulation of those resins of formula (I) involves the same problems as those in the formulation of the resins of formula (II) having an average degree of polymerization of from 10 to 10,000. In particular, the non-cros61inked anion exchange re~ins of formula (I) having an average degree of polymerization of larger than 10,000 are highly hygroscopic, therefore, the known tabletting methods requiring a predetermined amount of water were not directly applicable.
DISCLOSURE OF THE INVENTION
Having regard to the above-mentioned problems, the inventors have assiduously studied and, as a result, have found that a mixture comprising a non-crosslinked anion exchange resin of the following formula (I):
PCT1~97/03720 wn ~16~37 C1~
CO 1H3X~
\ o - (C~2)2 - N~ - CH2 ~ ~ /~ /
wherein X represents a physiologically-acceptable counter ion; and p represents an average degree of polymerization and i6 larger than lO,000, and at least silicon dioxide and crystalline cellulose can be formed into tablets on an industrial scale, without adding water thereto, and that the cores of the non-coated tablets as obtained above can be coated with a coating agent comprising cellulose in order to coat the tablets, and also that those non-coated and coated tablets are free from the above-mentioned problems. In addition, the inventors have further found that, by that the non-coated tablets which are highly hygroscopic are coated with such a coating agent comprising cellulose, the coated tablets do not only control the bitter of the compound of formula (I) but also prevent hygroscopic of the non-coated tablets without adding water content. Therefore these tablets are stable in long-term 6torage.
The present invention provides anion exchange resin-containing tablets as formed by tabletting a mixture comprising the non-crosslinked anion exchange resin of formula (I) ~nd at least silicon dioxide and crystalline cellulose but not containing water. The invention also provides a method for producing anion exchange resin-containing tablets, which comprises adding at least silicon dioxide and crystalline cellulose to the non-crosslinked anion exchange resin of formula (I) but not adding water thereto to give a mixture, followed by tabletting the mixture.
The invention further provides coated and non-crosslinked anion exchange resin containing tablets as produced by tabletting a mixture comprising the non-crosslinked anion exchanqe resin of formula (I) and at least silicon dioxide and cry~talline cellulose but not containing water followed by coating the resulting non-coated tablets with a coating material comprising a cellulosic substance, and provides a method for producing such coated tablets.
The preparations of the invention are characterized in that they contain a minimized amount of vehicles, or that is, they contain a highest possible amount of the active ingredient. The preparations of the invention can be WOg8/16237 PCT/~7/03720 produced in any continuous production lines on an industrial scale.
If the mixture to be tabletted into tablets according to the invention does not contain either one of silicon dioxide and crystalline cellulose, not only its ta~lettability is poor but also the fluctuation in the weight of the tablets formed ifi great, and in addition, the surfaces of the tablets formed are cracked and the edges thereof are chipped, resulting in that the yield of tablets with acceptable quality is greatly lowered (see Examples 4 and 5 in the present application).
BEST MODES OF CARRYING OUT THE INVENTION
The non-crosslinked anion exchange resin of formula (I)-for use in the present invention is described in detail hereinunder.
The counter ion X in the non-crosslinked anion exchange resin of formula (I) for use in the invention is not specifically defined if it is a physiologically-acceptable counter ion. For this, however, preferred are halides, sulfates and phosphates; more preferred are halide ions such as chloride, bromide, fluoride and iodide ions.
The average degree of polymerization p of the non-crosslinked anion exchange resin of formula (I) for use in the invention i~ larger than l0,000, preferably from larger than 10,000 to 50,000, more preferably from larger than 10,000 to 30,000, even more preferably from larger than 10,000 to 15,000. More concretely, the average degree of polymerization p is preferably from 10,001 to 50,000, more preferably from 10,001 to 30,000, even more preferably from 10,001 to 15,000.
One preferred example of the non-cros~linked anion exchange resin of formula (I) for use in the invention is poly(acryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride) having an average degree of polymerization, p, of from 10,001 to 30,000, more preferably from 10,001 to 15,000.
In order to obtain an average degree of polimerization p, the ordinary ways may be performed, preferably the following way may be performed;
Firstly, a molecular weight was measured with GPC
system aparatus (SHIMAZU SEISAKUSHO K.K. ), RI (differential refractive index detection) as a detector and TOSOH
G600OPWXL-G300OPWXL as a column, Column Temperatures 40 C
Mobile Phase: 50 mM-NaCl solution Flow Rate: 1 mL/min.
and then the measured molecular weight was divided by a basic structure unit (a molecular weight of monomer).
WO98116237 PCT/~7/03720 The non-crosslinked anion exchange resin of formula (I) for use in the invention can be produced in any ordinary method in which the corresponding monomers are prepared and then polymerized in an ordinary manner. More concretely, quaternary ammonium salts of the corresponding monomers are prepared and are polymerized to a sufficient degree in the presence of a polymerization initiator such as a radical polymerization initiator. If the polymerization is effected under a mild condition, the resulting polymer may have a small average degree of polymerization, p. Therefore, it iB desired to effect the polymerization to a sufficient degree.
Now, the preparations of the invention are described hereinunder.
The amount of the compound of formula ~I) to be in the non-coated tablets of the invention may be from 50 to 95 %
by weight, preferably from 70 to gO % by weight, more preferably from 75 to 90 % by weight, relative to the total weight of each non-coated tablet.
Silicon dioxide and crystalline cellulose to be used in the invention are not specifically defined, provided that their oral administration is admitted. From the commercial viewpoint, however, preferred are those which have heretofore been used in conventional oral medicines.
PCT/~7/03720 Wo ~/16237 Silicon dioxide is to well fluidize the mixture to be tabletted. For example, employable is colloidal silicon dioxide hydrate (e.g., white carbon), silicon dioxide (e.g.
silica gel, 6ilicic anhydride) and so on. Preferred is anhydrous, fine particulate silicon dioxide or light ~ilicic anhydride. Silicon dioxide for use in the invention has an apparent specific gravity of from 20 g/liter to 70 g/liter, preferably from 20 g/liter to 50 g/liter. Preferred is light silicic anhydride having a ~mall apparent specific gravity. The amount of silicon dioxide to be added may be from O.Ol to 5 % by weight, preferably from O.l to 3 % by weight, more preferably from O.l to l % by weight, relative to the total weight of each no~-coated tablet.
- Crystalline cellulose is preferably microcrystalline cellulose, and may have a mean grain size of from 5 to 50 microns, preferably from lO to 50 microns, more preferably from l~ to 30 microns. Its amount to be added may be from O.l to 30 % by weight, preferably from l to 30 % by weight, more preferably from lO to 30 ~ by weight, relative to the total weight of each non-coated tablet.
Regarding silicon dioxide, especially light ~ilicic anhydride added to the mixture to be tabletted in the invention, the increase in its amount and the decrease in it~ apparent specific gravity (bulk density) results in the W 098/16237 PCT/Jr97/03720 increase in the fluidity of the powdery mixture, while often worsening the tablettability (into compact tablets) of the mixture. Therefore, i~ silicon dioxide is added to the mixture in an amount of 5 parts or more, relative to the compound of formula (I), the tablettability of the mixture is poor thereby resulting in that the tablets formed are much cracked.
On the other hand, regarding crystalline cellulose added to the mixture to be tabletted in the invention, the increase in its amount and the decrease in its mean grain size results in the increase in the tablettability (into compact tablets) of the powdery mixture, while often lowering the fluidity of the mixture. In particular, if crystalline cellulose is added to the mixture in an amount of larger than 30 parts relative to the compound of formula (I), the weight of the tablets formed greatly fluctuates.
Since there is no significant reason for adding crystalline cellulose to the mixture in such an amount of larger than 30 parts, it ie desirable to add any inexpensive vehicle such as lactose to the mixture if the addition of a large amount of vehicles is needed.
Discussing it in more detail, the invention provides anion exchange resin-containing tablets as formed by tabletting a mixture comprising the non-crosslinked anion exchange resin of formula (I), and containing at least WO98/16237 PCTm~7103720 light silicic anhydride having a 6mall apparent specific gravity of from 20 gtliter to 70 g/liter, preferably from 20 g/liter to 50 g/liter, and crystalline cellulose having a mean grain size of from 10 microns to 50 microns, preferably from 10 microns to 30 micron~, but not containing water, and provide~ a method for producing the tablets.
Also in more detail, the invention provides anion exchange resin-containing tablets as formed by tabletting a mixture comprising the non-crosslinked anion exchange resin of formula tI), and containing at least silicon dioxide having a small apparent specific gravity of from 20 g~liter to 50 gtliter, preferably from 20 g/liter to 40 g/liter, and crystalline cellulose having a mean grain size of from 10 microns to 50 microns, preferably from 10 microns to 30 microns, but not containing water, in which the anion exchange resin i~ from 50 to 95 ~ by weight, preferably from 70 to 90 ~ by weight, more preferably from 75 to 90 ~
by weight, relative to the total weight of each tablet, and provides a method for producing the tablets.
The invention further provides coated, non-crosslinked anion exchange resin-containing tablets as produced by coating the non-coated tablets with a coating material comprising a cellulosic substance, and provide6 a method for producing the coated tablets.
Wo98116237 The non-coated tablets of the invention, which may be the cores of the coated tablets, may contain, in addition to the above-mentioned silicon dioxide and crystalline cellulose, any other conventional additives that are generally employable in forming tablets, within the range not interfering with the object of the invention. For example, the tablets of the invention may optionally contain any of vehicles, for example, bioses and monoses such as lactose, sucrose, glucose, mannitol and sorbitol, and starches such as potato starch, wheat starch, corn starch and rice starch; lubricants, for example, inorganic substances such as calcium phosphate and calcium sulfate, higher fatty acids and their metal salts (e.g., stearic acid, magnesium stearate), higher alcohols, talc, and synthetic aluminium silicate; disintegrators such as starches, sodium or potassium salt of carboxymethyl cellulose, methyl cellulose, carboxymethyl starch and sodium alginate; and binders such as starches, sucrose, gelatin, arabic gum, methyl cellulose, sodium carboxymethyl cellulose, polyvinyl pyrrolidone and polymethyl pyrrolidone The non-coated tablets of the invention, which may be the cores of the coated tablets, can be produced by mixing the constituent components and tabletting the resulting mixture. The order of adding the components to give the mixture is not specifically defined. Preferably, however, crystalline cellulose and silicon dioxide are first mixed, and then the compound of formula (I) is added thereto preferably gradually, and mixed togethe~. Then, the optional components may be added to and mixed with the resulting mixture.
The tabletting pressure is not specifically defined, but is preferably not larger than 2 tons.
The cellulosic substance to be in the coating material which is used in coating the non-coated tablets in the invention is not specifically defined, provided that it is a pH-independent and water-soluble one. Concretely, for example, employable are hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and methyl cellulose.
Preferred i8 hydroxypropylmethyl cellulose.
Those cellulosic substances may be used singly, but if desired, may be used along with a small amount of wax, titanium oxide, talc, hydroxypropyl cellulose with a low degree of substitution, polyethylene glycol, triethyl citrate or the like. In view of the strength of the coated film and of the economical aspect, polyethylene glycol (Macrogol) is preferably added to the coating material.
Regarding the concentration of the cellulosic substance in the coating liquid, if it iB too high, the amount of the cellulosic substance to be in the coated film is too much. Therefore, too high concentration of the cellulosic substance in the coating liquid is unfavorable.
Preferably, the concentration of the cellulosic substance is smaller than 20 % by weight, more preferably from 6 to 15 % by weight or so. Where polyethylene glycol (Macrogol) is added to the coating liquid, it~ concentration is preferably from 1 to 50 % by weight or so, more preferably from 5 to 40 % by weight or 60, relative to the cellulosic substance.
Acid-soluble, film-forming substances are also employable for coating the non-coated tablets. For example, employable are coating materials capable of dissolving in gastric acids, such as diethylamino methacrylate, polyvinyl acetal diethylaminoacetate (AEA), dimethylaminoethyl methacrylate-methyl methacrylate copolymer (be on the market as EUDRAGIT (methyl methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate copolymer))~ cellulose acetate N,N-di-n-butylhydroxypropyl ether (CABP), etc.
The coating method is not specifically defined, but preferred is spray-coating.
The amount of the coating material to be applied to the non-coated tablets is preferably such that the coated film may be from 1 to 10 % by weight relative to each non-coated tablet (core). To mask the bitterness of the non-coated tablets, the tablets may be coated with the coated film of 1 % by weight or more. However, even if the WO98116237 PCT1~97103720 tablets are coated with the film of larger than 10 % by weight, such produces no more advantage~. Most preferably, the coated film is about 3 % by weight. Prior to coating them, it is preferable to measure the water content of the non-coated tablets (cores), and the coating is continued until the increa~e in the water content of the coated tablets is no more recognized.
EXAMPLES
Now, the invention i6 described in more detail hereinunder with reference to the following Examples.
However, it is obvious that the invention is not restricted ~y those Examples but may encompass any other changes and modifications without overstepping its scope and spirit.
Example 1:
(1) Mixing Step:
To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Method:
As in the mixture formulation mentioned below, 1000 g of crystalline cellulose and 50 g of light silicic anhydride were weighed, put into the mixer, and mixed therein for 5 minutes.
The total amount of poly(acryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride) (of formula (I) where X
is chloride ion - hereinafter referred to as "compound 1") having an average degree of polymerization of 12,000 was divided into four portions, which were separately added to the mixture one after another at intervals of 5 minutes, with still mixing it.
Next, 50 g of magnesium stearate was weighed, added to the mixture and further mixed for 1 minute.
(1-2) Mixture Formulation (10 kg):
Compound 1 8900 g Crystalline Cellulose 1000 g (be on the market as Avicel PH-F20 (average grain 6ize: 17 microns)) Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent specific gravity (bulk density):
30 g/liter) (2) Tabletting Step:
To form the mixture into tablets, used was the following tabletting device:
Tabletting Device: Rotary tabletting machine, HT-AP15SS
(Hata Ironworks Co.) WO98/16237 PCT/~7/03720 (2-l~ Tabletting Condition Number of revolution: 35 rpm Thickness of tablet: ~ mm Hardness of tablet: 7 or more Vertical pres6ure for tabletting: 2 tons or less Feeding system: forced feeder used (3) Coating Step:
To coat the non-coated tablets, used was the followLng coating devices Coating Device: Dria Coater 650 (POWREX) (3-1) Coating Method:
7 kg of the non-coated tablets produced in the previous step (2) were put into a coating pan, in which the temperature of the vapor to be absorbed by the tablets was kept at 80~C without revolving the pan (number of revol~tion: 0 rpm) until the temperature of the vapor as discharged from the pan became constant. In this stage, the temperature of the discharged vapor was confirmed to be 50~C or higher. 20 tablets were sampled out of the pan and weighed. Then, they were ground, and their water content was measured. After this, a coating liquid having the composition mentioned below was sprayed over the tablets in the pan at a spraying rate of 12 g/min, while the pan was revolved at 7 rpm. After 30 minutes, the number of revolution of the pan was changed to 15 rpm, and the spraying was further continued at a spraying rate of about 18 g/min. At regular intervals during the spraying, 20 tablets were sampled out, and their weight and water content were measured. When no increa6e in the water content of the sampled, coated tablets was recognized and when the weight of the coated tablets became 103 % of the non-coated tablets, the spraying was stopped. Then, the pan was still revolved at 5 rpm for about 60 minutes to dry the coated tablets.
(3-2) Coating Liquid Formulations Hydroxypropylmethyl Cellulose 2910400 g Macrogol 6000 120 g Ion-exchanged Water 4600 g Example 2 (1) Mixing Steps To mix the constituent components, used was the following mixing device.
Mixing Devices V-type mixer, FMV100 (~OWREX) (1-1) Mixing Method:
AB in the mixture formulation mentioned below, 2000 g of cry6talline cellulose and 50 g of light silicic WO98/16237 pcTl~s7lo372o anhydride were weighed, put into the mixer, and mixed therein for 5 minutes.
The total amount of compound l wa~ divided into four portions, which were separately added to the mixture one after another at intervals of 5 minutes, with 6till mixing it.
Next, 50 g of magnesium stearate was weighed, added to the mixture and further mixed for l minute.
(l-2) Mixture Formulation (lO kg) Compound l 7900 g Crystalline Cellulose lO00 g (be on the market as Avicel PH-3lO (average grain sizes 40 microns)) Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent specific gravity (bulk den~ity):
50 g/liter) (2) Tabletting Step, Coating Step:
In the same manner as in Example l, the mixture was tabletted and coated.
Example 3 (l) Mixing Steps To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Method:
As in the mixture formulation mentioned below, 1000 g of crystalline cellulose, 550 g of lactose and 50 g of light silicic anhydride were weighed, put into the mixer, and mixed therein for 5 minutes.
The total amount of compound 1 was divided into four portions, which were separately added to the mixture one after another at intervals of 5 minutes, with still mixing it.
Next, 50 g of magne~ium stearate wa6 weighed, added to the mixture and further mixed for 1 minute.
(1-2) Mixture Formulation (10 kg):
Compound 1 8350 g Crystalline Cellulose 1000 g (be on the market as Avicel PH-F20 (average grain size: 17 microns)) Lactose 550 g Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent 6pecific gravity (bulk density):
W O98/16237 PCT/JPg7/~3720 50 g~liter) (2) Tabletting Step, Coating Step:
In the same manner as in Example 1, the mixture wa~
tabletted and coated.
Example 4 (1) Mixing Step, Tabletting Step:
In the same manner as in Example 1, the constituent components were mixed and tabletted.
(2) Coating Step:
(2-1) Coating Method~
~ n the same manner as in Example 1, the non-coated tablets were coated with the coating liquid mentioned below, and then dried. Next, 5 g of carnauba wax was added to the coating pan still containing the dried, coated tablets therein, and the pan was further revolved at 5 rpm for 5 minutes.
(2-2) Coating Li~uid Formulation:
Hydroxypropylmethyl Cellulose 2910400 g Macrogol 6000 120 g Titanium oxide 28 g Ion-exchanged Water 4000 g PCT/~7/03720 Wo ~116~7 ~2-3) Lubricant:
Powdery Carnauba Wax 5 g Example 5 Non-coated tablets were produced in the same manner as in Example l-(l) and (2), except that poly(acryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride (of formula (I) where X is chloride ion)) having an average degree of polymerization of 13,000 was used.
Next, these were coated in the same manner as in Example l-(3) to obtain coated tablets.
Example 6 Non-coated tablets were produced in the same manner as in Example l-(l) and (2), except that poly(acryloyloxyethyl-N,N-dimethyl-N-benzylammonium chloride (of formula (I) where X is chloride ion)) having an average degree of polymerization of l~,000 was used.
Next, these were coated in the same manner as in Example l-(3) to obtain coated tablets.
Comparative Example l (l) Mixing Step:
To mix the con6tituent components, used was the following mixing device.
pcTl~s7l~372o WO g8/16237 Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Method:
As in the mixture formulation mentioned below, 1000 g of crystalline cellulose and 50 g of light ~ilicic anhydride were weighed, put into the mixer, and mixed therein for 5 minutes.
The total amount of compound 1 was divided into four portions, which were separately added to the mixture one after another at intervals of 5 minute~, with still mixing it.
Next, 50 g of magnesium stearate was weiqhed, added to the mixture and further mixed for 1 minute.
Since it was difficult to mix compound 1 and water, ~90 g of water sprayed over the sy~tem being mixed.
(1-2) Mixture Formulation (10 kg):
Compound 1 8010 g Water 890 g Crystalline Cellulose 1000 g (be on the market as Avicel PH-F20 (average grain size: 17 microns)) Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent specific gravity (bulk density) t 30 g/liter) Comparative Example 2:
(1) Mixing Step:
To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Method:
As in the mixture formulation mentioned below, 1000 g of crystalline cellulose and 50 g of light silicic anhydride were weighed, put into the mixer, and mixed therein for ~ minutes.
The total amount of compound 1 was divided into four portions, which were separately added to the mixture one after another at intervals of S minutes, with still mixing it.
Next, 50 g of magnesium stearate was weighed, added to the mixture and further mixed for 1 minute.
(1-2) Mixture Formulation (10 kg):
Compound 1 ~900 g Crystalline Cellulose 1000 g (be on the market as Avicel PH-301 (average grain size: 40 microns)) Magnesium Stearate 50 g Light Silicic Acid 50 g (apparent specific gravity (bulk density):
30 g/liter) WO98/16237 PCT/~97/03720 (2) Tabletting Step, Coating Step:
In the same manner as in Example l, the mixture was tabletted and coated.
Comparative Example 3:
(l) Mixing Steps To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMVl00 (POWREX) (l-l) Mixing Method:
As in the mixture formulation mentioned below, l000 g of crystalline cellulose and 50 g of light silicic anhydride were weighed, put into the mixer, and mixed therein for S minutes.
The total amount of compound l was divided into four portions, which were separately added to the mixture one after another at intervals of 5 minutes, with still mixing it.
Next, 50 g of magnesium stearate wa~ weighed, added to the mixture and further mixed for l minute.
(1-2) Mixture Formulation (l0 kg):
Compound l 8900 g Cry6talline Cellulose l000 g (be on the market as Avicel P~-302 (average grain sizes l20 microns)) Magneslum Stearate 50 q Light Silicic Acid 50 g (apparent specific gravity (bulk densi~y):
30 g/liter) (2) Tabletting Step, Coating Step:
In the same manner as in Example 1, the mixture was tabletted and coated.
Comparative Example 4:
(1) Mixing Step:
To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMV100 (POWREX) (1-1) Mixing Methods A~ in the mixture formulation mentioned below, 50 g of light silicic anhydride was weighed and put into the mixer.
The total amount of compound 1 was divided into four portions, which were ~eparately added to the anhydride one after another at intervals of 5 minutes, with mixing it.
Next, 50 g of magneEium stearate wa~ weighed, added to the mixture and further mixed for 1 minute.
(1-2) Mixture Formulation (10 kg):
Compound 1 9900 g Magnesium Stearate 50 g PC~1~97103720 Light Silicic Acid 50 g ~apparent specific gravity (bulk density):
30 g/liter) (2) Tabletting Step, Coating Step:
In the same manner as in Example l, the mixture wa~
tabletted and coated.
Comparative Example 5:
(l) Mixing Step:
To mix the constituent components, used was the following mixing device.
Mixing Device: V-type mixer, FMVl00 (POWREX~
(l-l) Mixing Method:
As in the mixture formulation mentioned below, l000 g of crystalline cellulose was weighed and put into the mixer.
The total amount of compound l was divided into four portions, which were separately added to the crystalline cellulose one after another at intervals of 5 minutes, with mixing it.
Next, 50 g of magnesium stearate was weighed, added to the mixture and further mixed for l minute.
(1-2) Mixture Formulation (l0 kg):
Compound l 8950 g Crystalline Cellulose l000 g PCT/~7/03720 (trade name: Avicel PH-F20 (average grain size:
l7 micron6)) Magne~ium Stearate 50 g (2) Tabletting Step, Coating Step:
In the same manner as in Example l, the mixture was ta~letted and coated.
Comparative Example 6:
(l) Mixing Step:
To mix the constituent components, used wa6 the following mixing device.
Mixing Device: V-type mixer, FMVl00 (POWREX) (l-l) Mixing Method:
A6 in the mixture formulation mentioned below, 9950 g of compound l and 50 g of magnesium stearate were weighed, put into the mixer, and mixed therein for l minute.
(1-2) Mixture Formulation (l0 kg1s Compound l 9950 g Magnesium Stearate 50 g (2) Tabletting Step, Coating Step:
In the 6ame manner a6 in Example l, the mixture was tabletted and coated.
Comparative Example 7:
rCTlJP97103720 Wo98116237 Non-coated tablets were produced in the same manner as in Example 1, but these were not coated herein.
Te~t Example 1:
The samples prepared above were tested for their powder flowability and compres~ibility (tablettability).
A~ in Table 1, the fluctuation in the weight of non-coated tablets indicate~ the powder ~lowa~ility, and the frequency of chipping and crackin~ of coated tablet6, for which the non-coated tablets were produced by compres 6 ing the powdery mixture at a pressure of 2 t~ns or lower, indicates the compressibility. Since the non-coated tablets were highly hygroscopic, their weight increased in the abrasion ~est.
The outward appearance of the tested tablet~ indicates their compressibility.
The test data are shown in Table 1.
Table 1 Fluctuation in Weight of Non-coated Chipplng, Cracking Tablettability TablP-s CXAIIIP e sma no A
Examp e _ sma no A
Examp e sma no A
Co~"part~ ~e Example 1u"~abletlable Comparatlve Example 2 small surface cracked C
Comparative surface cracked, Example3 small edges chipped C
Co",par~ e surface cracked, Example 4 small edges chipped C
Comparatlve Example 5 medium no B
Comparative surface cracked, Example 6 great edges chipped D
W O 9%/16237 PCT/JP97/03720 In Comparative Example 1 in which the components were mixed along with water, the components could not be well mixed because of their deliquescence and cobwebbing, and could not be tabletted.
In all Examples and Comparative Examples in which the components were mixed in the absence of water, it wa6 possible to tablet the mixtures and coat the non-coated tablets. However, only sample~ in Example 1, Example 2 and Example 3 involved no problem with respect to their powder flowability and compressibility.
In Comparative Example 4, crystalline cellulose was not used; in Comparative Example 5, light silicic anhydride was not used; and in Comparative Example 6, both the two were not used. In the absence of crystalline cellulose, the tablettability (compressibility~ of the mixture i8 extremely poor, and the surface of the coated tablets was cracked. In the absence of light silicic anhydride, the powder flowability of the mixture was poor, and the fluctuation in the wei~ht of the tablets increased. In the absence of the two, crystalline cellulose and light silicic anhydride, the fluctuation in the weight of the tablet~
greatly increased, and the tablets were cracked and chipped, or that is, the tablettability of the mixture was poor.
WO98/lQ37 PCT/~97/03720 In Comparative Example 2, crystalline cellulose having a mean grain size of 40 microns was used; and in Comparative Example 3, crystalline cellulose having a mean grain size of 120 microns was used. In those two, used was light silicic anhydride having an apparent specific gravity (bulk density) of 30 g/liter. Even though crystalline cellulose having a large mean grain size was used, the mixture could be tabletted if light silicic anhydride having a small apparent 6pecific gravity (bulk density) was added thereto (see Example 2). However, as in those Comparative Examples, if light 8i1iCiC anhydride having a large apparent specific gravity (bulk density) was added to the mixture, it is known that the tablets were cracked or chipped and the tablettability of the mixture was poor.
AB in Example l in which were used light silicic anhydride having a small apparent specific gravity (bul~
density) and crystalline cellulose having a small mean grain size, the tablets formed had a high chemical (active ingredient) content. Thus, the tablets of the invention are advantageous in that the dose of the tablets can be decreased. In addition, the mixture formulation for the tablets of the invention can be stably tabletted in continuous production plants directly after the step of mixing it, without requiring any additional step of granulating it.
PCT/~97103720 Test Example 2:
The tablets of the invention are deformed when their water content is larger than 7 %. In addition, after having absorbed more water, they become deliquescent. The stability of the tablets can be ensured by coating them.
To evaluate their stability, the tablets of Example l, Example 4 and Comparative Example 7 were kept at 60~C and 90 % RH for 20 minutes, and the presence or absence of the change in their form was checked. In addition, they were tested for their bitterness by putting them in the mouth for 30 seconds. The test data are shown in Table 2.
Table 2 Defo~ a~lon ~ittt~ ness Ex~mple no ~ o Ex~mple ~ no \ o Coi"ph~tve ExAmple 7 yes Yes The data indicate that the stability of the coated tablets is high and that the coated tablet~ are easy to take as their bitterness was masked.
The tablets obtained in Examples 5 and 6 were also subjected to the same tests in Test Examples l and 2, and produced the same good results.
The non-crosslinked anion exchange resin of formula (I) of the invention exhibits excellent pharmaceutical WO98/16237 PCT/~7/03720 effects and is useful as a cholesterol depressant for oral administration. According to the tabletting method of the invention, the peroral cholesterol depre6sant of formula (I) with good pharmaceutical effects can be formed into medicines that are easy to take.
INDUSTRIAL APPLICABILITY
The invention provides anion exchange resin-containing, cholesterol-depressant tablets for oral administration, which are superior to any other conventional ones in that their do6e may be decrea~ed and that they are ea6y to take.
In addition, the tabletting method of the invention is greatly advantageous in that it does not require any additional granulating step. The tablets of the invention may be coated with a coating material compri6ing a cellulosic material, and the resulting coated tablets are easier to take as being not bitter.
The method of the invention is advantageous as being applicable to industrial plants.
Claims (10)
1. Anion exchange resin containing tablets as formed by mixing a non-crosslinked anion exchange resin of formula (I):
wherein X represents a physiologically-acceptable counter ion; and p represents an average degree of polymerization, and is larger than 10,000, silicon dioxide and crystalline cellulose, in the absence of water, followed by tabletting the resulting mixture.
wherein X represents a physiologically-acceptable counter ion; and p represents an average degree of polymerization, and is larger than 10,000, silicon dioxide and crystalline cellulose, in the absence of water, followed by tabletting the resulting mixture.
2. Tablets as claimed in claim 1, wherein the amount of silicon dioxide added is from 0.1 to 5 % by weight.
3. Tablets as claimed in claim 1 or 2, wherein the amount of crystalline cellulose added is from 1 to 30 % by weight.
4. Tablets as claimed in any one of claims 1 to 3, wherein silicon dioxide added has an apparent specific gravity of from 20 g/liter to 70 g/liter, and crystalline cellulose added has a mean grain size of from 10 to 50 microns .
5. Anion exchange resin containing coated tablets as formed by coating cores of the non-coated tablets of any one of claims 1 to 4 with a coating agent.
6. Coated tablets as claimed in claim 5, wherein the coating agent comprises cellulose.
7. Coated tablets as claimed in claim 6, wherein the cellulose is hydroxypropylmethyl cellulose.
8. Coated tablets as claimed in any one of claims 5 to 7, wherein the non-coated tablets are coated with from 1 to 10 % by weight of the coating agent.
9. A method for producing the tablets of any one of claims 1 to 4.
10. A method for producing the coated tablets of any one of claims 5 to 8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8-293328 | 1996-10-15 | ||
| JP29332896A JP4010585B2 (en) | 1996-10-15 | 1996-10-15 | Tablets containing anion exchange resin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2240402A1 true CA2240402A1 (en) | 1998-04-23 |
Family
ID=17793408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002240402A Abandoned CA2240402A1 (en) | 1996-10-15 | 1997-10-15 | Anion exchange resin-containing tablets |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6197290B1 (en) |
| EP (1) | EP0873129B1 (en) |
| JP (1) | JP4010585B2 (en) |
| KR (1) | KR19990072020A (en) |
| CN (1) | CN1111413C (en) |
| AT (1) | ATE216248T1 (en) |
| CA (1) | CA2240402A1 (en) |
| DE (1) | DE69712033T2 (en) |
| DK (1) | DK0873129T3 (en) |
| ES (1) | ES2176792T3 (en) |
| ID (1) | ID21038A (en) |
| PT (1) | PT873129E (en) |
| RU (1) | RU2180219C2 (en) |
| TW (1) | TW528605B (en) |
| UA (1) | UA51686C2 (en) |
| WO (1) | WO1998016237A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000008063A1 (en) * | 1998-08-05 | 2000-02-17 | Hisamitsu Pharmaceutical Co., Inc. | Process for producing cationic polymer |
| US6413394B1 (en) * | 1999-07-08 | 2002-07-02 | Thomas Y. Shen | Disposable plate electrode with biological active film |
| KR100790056B1 (en) * | 2000-09-06 | 2007-12-31 | 미쯔비시 웰 파마 가부시키가이샤 | Granular preparations for oral administration |
| JPWO2002043761A1 (en) * | 2000-11-28 | 2004-04-02 | 三菱ウェルファーマ株式会社 | Anti-obesity agent and health food |
| CN1953756A (en) | 2004-03-26 | 2007-04-25 | 三菱制药株式会社 | Insulin resistance improving agent |
| US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| EP2039363B1 (en) | 2006-06-16 | 2013-01-02 | Mitsubishi Tanabe Pharma Corporation | Agent for prevention and/or treatment of glomerulopathy |
| US20090252794A1 (en) | 2006-08-09 | 2009-10-08 | Tetsuya Suzuki | Tablet |
| RU2668499C2 (en) * | 2015-03-12 | 2018-10-01 | Закрытое Акционерное Общество "Фармфирма "Сотекс" | Pharmaceutical composition in form of tablets with enteric coating and method of preparation thereof |
| CN107233933A (en) * | 2017-05-09 | 2017-10-10 | 安徽皖东化工有限公司 | A kind of preparation method of water body purification styrenic anion exchanger resin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI67483C (en) * | 1977-02-17 | 1985-04-10 | Merck & Co Inc | PROCEDURE FOR THE FRAMEWORK OF ETHCYCLE ADMINISTRATION OF PHARMACOLOGICAL PRODUCT AGAINST GALLSYRAK COMPLEX BILDANDE ADSORBATE PREPARATION |
| SE445013B (en) * | 1979-06-21 | 1986-05-26 | Landstingens Inkopscentral | Means for preventing or treating infections by humans and animals |
| JPH01172324A (en) | 1987-12-15 | 1989-07-07 | Armour Internatl Co | Colestyramine composition and production thereof |
| ATE96030T1 (en) * | 1988-03-24 | 1993-11-15 | Taisho Pharmaceutical Co Ltd | CHOLESTEROL-LOWERING INGREDIENTS. |
| US5178854A (en) * | 1988-03-24 | 1993-01-12 | Taisho Pharmaceutical Co., Ltd. | Cholesterol-lowering agents |
| JPH02286621A (en) | 1989-04-26 | 1990-11-26 | Mitsubishi Kasei Corp | Oral cholesterol lowering agent |
| DE4121127A1 (en) * | 1991-06-26 | 1993-01-14 | Rettenmaier & Soehne Gmbh & Co | Auxiliary esp. binder for use in dry direct tabletting of medicaments - comprises cellulose@ laminated with e.g. highly disperse silica by friction or milling |
| DE69328741T2 (en) * | 1992-01-14 | 2000-09-07 | Hisamitsu Pharmaceutical Co | Uncrosslinked anion exchange resin and pharmaceutical composition containing the same |
| JP3552285B2 (en) | 1993-08-03 | 2004-08-11 | 三菱化学株式会社 | Oral cholesterol lowering agent |
| TW438608B (en) * | 1995-08-02 | 2001-06-07 | Hisamitsu Pharmaceutical Co | A tablet containing anion exchange resin |
-
1996
- 1996-10-15 JP JP29332896A patent/JP4010585B2/en not_active Expired - Fee Related
-
1997
- 1997-10-15 UA UA98073742A patent/UA51686C2/en unknown
- 1997-10-15 TW TW086115101A patent/TW528605B/en not_active IP Right Cessation
- 1997-10-15 AT AT97944125T patent/ATE216248T1/en not_active IP Right Cessation
- 1997-10-15 WO PCT/JP1997/003720 patent/WO1998016237A1/en not_active Application Discontinuation
- 1997-10-15 ES ES97944125T patent/ES2176792T3/en not_active Expired - Lifetime
- 1997-10-15 CA CA002240402A patent/CA2240402A1/en not_active Abandoned
- 1997-10-15 ID IDW980023A patent/ID21038A/en unknown
- 1997-10-15 DE DE69712033T patent/DE69712033T2/en not_active Expired - Fee Related
- 1997-10-15 RU RU98113319/14A patent/RU2180219C2/en active
- 1997-10-15 CN CN97191436A patent/CN1111413C/en not_active Expired - Fee Related
- 1997-10-15 US US09/091,069 patent/US6197290B1/en not_active Expired - Fee Related
- 1997-10-15 PT PT97944125T patent/PT873129E/en unknown
- 1997-10-15 DK DK97944125T patent/DK0873129T3/en active
- 1997-10-15 EP EP97944125A patent/EP0873129B1/en not_active Expired - Lifetime
- 1997-10-15 KR KR1019980704313A patent/KR19990072020A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1204965A (en) | 1999-01-13 |
| ID21038A (en) | 1999-04-08 |
| UA51686C2 (en) | 2002-12-16 |
| DE69712033T2 (en) | 2002-08-22 |
| WO1998016237A1 (en) | 1998-04-23 |
| JPH10114661A (en) | 1998-05-06 |
| KR19990072020A (en) | 1999-09-27 |
| DK0873129T3 (en) | 2002-07-01 |
| US6197290B1 (en) | 2001-03-06 |
| EP0873129A1 (en) | 1998-10-28 |
| CN1111413C (en) | 2003-06-18 |
| AU723340B2 (en) | 2000-08-24 |
| JP4010585B2 (en) | 2007-11-21 |
| ATE216248T1 (en) | 2002-05-15 |
| TW528605B (en) | 2003-04-21 |
| EP0873129B1 (en) | 2002-04-17 |
| AU4572697A (en) | 1998-05-11 |
| ES2176792T3 (en) | 2002-12-01 |
| DE69712033D1 (en) | 2002-05-23 |
| RU2180219C2 (en) | 2002-03-10 |
| PT873129E (en) | 2002-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0878198B1 (en) | Tablets containing an anion exchange resin | |
| EP0187703B1 (en) | Sustained release preparation | |
| US5667801A (en) | Sustained release heterodisperse hydrogel systems for insoluble drugs | |
| AU599058B2 (en) | Sustained release compositions comprising hydroxypropyl cellulose ethers | |
| US6048548A (en) | Sustained release heterodisperse hydrogel systems-amorphous drugs | |
| JP3382950B2 (en) | Sustained release matrix for pharmaceuticals | |
| US8663698B2 (en) | Solid dispersion preparation | |
| CA2240402A1 (en) | Anion exchange resin-containing tablets | |
| JP2609022B2 (en) | Polycarbophil calcium-containing preparation | |
| JP2000514057A (en) | Solid solution of antifungal agent with enhanced bioavailability | |
| US5087454A (en) | Ibuprofen tablet | |
| AU723340C (en) | Anion exchange resin-containing tablets | |
| JP3963982B2 (en) | Tablets containing anion exchange resin | |
| JP2000034224A (en) | Sustained-release tablet, additive composition for the tablet, and their production | |
| JPH08198761A (en) | Preparation of containing calcium polycarbophil | |
| WO2007090595A1 (en) | Solid formulations of valacyclovir hydrochloride | |
| CN112023056A (en) | Fluconazole pharmaceutical composition and preparation method thereof | |
| JP2002173428A (en) | Clarithromycin tablet and method for producing the same | |
| Gandhi et al. | Controlled-Release Formulations of Azithromycin | |
| CA2174538A1 (en) | Base for sustained-release preparation, sustained-release preparation, and process for producing the preparation | |
| JPH05229936A (en) | Granular pharmaceutical for internal use | |
| AU770001B2 (en) | Sustained release heterodisperse hydrogel systems - amorphous drugs | |
| JPH1135488A (en) | Prostaglandin agent improved in stability | |
| JPH0640923A (en) | Hard capsule of cytarabine octaphosphate | |
| WO1993010775A1 (en) | Process and composition for the development of controlled release gemfibrozil dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |